



Introduction

A homogeneous luminescent immunoassay detection technology that generates light as the result of the interaction of HRP and acridan in the presence of hydrogen peroxide was evaluated in the validation of a pharmacokinetic (PK) assay for human IgG drug in rat serum. A commercially available SPARCL kit was purchased and an automated robotic pipetting station was used for liquid handling. This study evaluated the possibility of an affordable and off the shelf solution for automated PK assays for human IgG drugs dosed in preclinical species. The automated robotic pipetting station provided the liquid handling in the execution of the SPARCL commercial kit and was investigated for labor hours required, and assay performance including; dynamic range, minimum required dilution, precision, accuracy and total error.

SPARCLTM Technology

SPARCLTM (Spatial Proximity Analyte Reagent Capture Luminescence) technology is a proximity dependent chemiluminescent detection method. In a SPARCL assay, a chemiluminescent compound (acridan) is brought into close proximity to an oxidative enzyme (horseradish peroxidase, HRP) through specific antigen/antibody interaction. A flash of light proportional to the quantity of analyte present in the sample is generated upon addition of a trigger solution containing hydrogen peroxide. A background reducing agent (BGR) is often used to enhance S/N ratios. There is no need to remove excess reactants. There are no washing steps.



Figure 1. SPARCL key components. A. HRP labeled Antibody. B. Immunoassay target (analyte). C. 96 well low binding white plate. D. Acridan labeled Antibody. E. SPARCL Kit. F. Luminometer.

LUMIGEN is a registered trademark of Lumigen, Inc. SPARCL is for research use only and not for diagnostic purposes.

An Automated Pharmacokinetic Immunoassay Using Spatial Proximity Analyte Reagent Capture Luminescence (SPARCL) for Human IgG Drugs in Preclinical Species **2017 AAPS NBC #M1018**

Mark J. Cameron and Kristen C. Pauly, Lumigen, Inc., Southfield, MI 48033, USA



Figure 3. A typical SPARCL luminescence profile. Note that the time is on the X-axis and is from zero to 1 second. Relative light units (RLU) is on the Y-axis. There is a characteristic spike in light at 0.15 seconds after addition of trigger solution and predictable decay following the spike.



Figure 4. The Andrew pipetting station. Andrew uses commonly used laboratory pipets and pipet tips to perform all the liquid handling steps of the SPARCL immunoassay method.

Pennsylvania).

Humira: Also known as Adalimumab, is a fully human recombinant immunoglobulin, is IgG1 and is an anti-TNF monoclonal antibody. It was obtained from the local pharmacy.

Andrew 1000G liquid handling robot: Andrew Alliance (Boston, Massachusetts).

Pipets: Gilson, Pipetman (Middleton, Wisconsin).

Matrix: Rat serum. Bioreclamation (Baltimore, Maryland). Used at 10% in assay buffer. Assay buffer provided by Life Diagnostics.

Luminometer: BMG LabTech's LUMIstar Omega.

Methods:

The SPARCL PK kit was run according to the directions provided by the manufacturer (Life Diagnostics) by giving the pipetting instructions to the Andrew robot. Briefly, Andrew made the dilutions for the standard curve and QC's, pipetted the antibodies, calibrators and QC's into the wells of the 96 well plates.

The 96 well plate was incubated at room temperature for 30 minutes on a orbital shaker set at 350 revolutions per minute. After the incubation time was complete, the plate was moved to the LUMIstar Omega luminometer. The LUMIstar was instructed to inject the trigger solution and collect the emitted light.

Results							
ng	g/mL	Replicate 1	Replicate 2	Average	SD	CV	
		RLU	RLU				
1	100	171374	178839	175107	5279	3.0	
	50	151411	147312	149362	2898	1.9	
	25	102887	104563	103725	1185	1.1	
1	12.5	71995	77074	74535	3591	4.8	
6	5.25	38419	38526	38473	76	0.2	
3.	.125	15063	15684	15374	439	2.9	
1.	.625	7811	9456	8634	1163	13.5	
	0	573	572	573	1	0.1	
e 1. Typical standard curve data. RLU is Relative Light Units.							

	QC High	QC Low	
	ng/mL	ng/mL	
	19.6	4.6	
	19.8	4.1	
	19.3	4.6	
	19.0	4.5	
	18.8	4.7	
	19.5	4.6	
Average	19.3	4.5	
SD	0.4	0.2	
CV	2.0	4.7	
RE	-3.5	-10	
TE	55	147	

Table 2. Quality Control samples, high (20 ng/mL) and low (5 ng/mL). Concentration values interpolated from the standard curve are reported.

Conclusions and Future Direction

- The use of the Andrew robot with the Life Diagnostics SPARCL PK kit provides an assay that is accurate and precise for Humira in rat matrix.
- The Andrew robot and the Life Diagnostics SPARCL PK kit reduces human input and error, offers improvement in workflow and efficiencies.
- The Andrew system offers compliant software which may make the system useful in regulated laboratories.
- The combination of the Andrew robot with the Life Diagnostics SPARCL kit may be a solution for labs measuring IgG drug concentration in a preclinical setting.
- The combination of the Andrew robot with the Life Diagnostics SPARCL PK kit may be a way for CRO's to improve efficiencies, reduce PK assay development time and cost, reduce labor and increase profitability.